Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-117 in Glaucoma or Ocular Hypertension (AYAME Study)
NCT02623738Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omidenepag isopropyl in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Dec 2015; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02623738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623738.